ArticleAmerican journal of translational research2026
ECE1c promotes glioblastoma invasion via the ROCK2-MYH10 axis and interaction with ACTB.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma is the most malignant primary intracranial tumor and is characterized by rapid growth, diffuse invasion, and notable therapeutic resistance. The mesenchymal subtype of glioblastoma multiforme (GBM) is the most aggressive, but the underlying regulatory network of this phenotype has not yet been fully elucidated.
methodsBioinformatic analysis was performed to identify the heterogeneity of ECE1 expression and its prognostic roles. Cytological experiments were conducted to evaluate the function of ECE1 in GBM cell lines. Tumor xenograft models were established to access intracranial GBM growth
resultsIn the present study, our analyses revealed that ECE1 is closely associated with the mesenchymal subtype, CD44 expression, and prognosis of GBM. We found that ECE1c was the most common isoform in GBM. The knockdown of ECE1 reduced both the proliferation and invasiveness of GBM cells, whereas overexpression of ECE1c promoted tumor malignancy. Mechanistic studies revealed that ECE1c activates the ROCK2 signaling pathway and interacts with ACTB, thereby modulating cytoskeletal remodeling and promoting pseudopodia formation, which together increase the invasive capacity of GBM.
conclusionOur results indicate that ECE1c is a key regulator of GBM invasion through ROCK2 activation and interaction with ACTB. Targeting ECE1c may represent a viable therapeutic strategy for treating invasive GBM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.